These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 16886912)

  • 1. Review article: evolutionary advances in the delivery of aminosalicylates for the treatment of ulcerative colitis.
    Cohen RD
    Aliment Pharmacol Ther; 2006 Aug; 24(3):465-74. PubMed ID: 16886912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review article: new drug formulations, chemical entities and therapeutic approaches for the management of ulcerative colitis.
    Ng SC; Kamm MA
    Aliment Pharmacol Ther; 2008 Oct; 28(7):815-29. PubMed ID: 18627362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel 5-aminosalicylic acid formulations in ulcerative colitis: old dog, new tricks.
    Wilson J
    Gastroenterol Nurs; 2008; 31(4):286-92. PubMed ID: 18708833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis--results from a randomized-controlled trial.
    Raedler A; Behrens C; Bias P
    Aliment Pharmacol Ther; 2004 Dec; 20(11-12):1353-63. PubMed ID: 15606398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New approaches to adherence issues when dosing oral aminosalicylates in ulcerative colitis.
    Tindall WN
    Am J Health Syst Pharm; 2009 Mar; 66(5):451-7. PubMed ID: 19233992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention.
    Sandborn WJ
    Rev Gastroenterol Disord; 2006; 6(2):97-105. PubMed ID: 16699478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reformulation of an aminosalicylate: an example of the importance of pill burden on medical compliance rates.
    Osterman MT; Lichtenstein GR
    Methods Find Exp Clin Pharmacol; 2009; 31(1):41-6. PubMed ID: 19357797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review article: aminosalicylates for distal colitis.
    Gionchetti P; Rizzello F; Morselli C; Tambasco R; Campieri M
    Aliment Pharmacol Ther; 2006 Oct; 24 Suppl 3():41-4. PubMed ID: 16961744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review article: aminosalicylates in inflammatory bowel disease.
    Hanauer SB
    Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 4():60-5. PubMed ID: 15352896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis.
    Marshall JK; Irvine EJ
    Am J Gastroenterol; 2000 Jul; 95(7):1628-36. PubMed ID: 10925961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Colonic targeting of aminosalicylates for the treatment of ulcerative colitis.
    Klotz U
    Dig Liver Dis; 2005 Jun; 37(6):381-8. PubMed ID: 15893274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review article: induction therapy for patients with active ulcerative colitis.
    Travis SP
    Aliment Pharmacol Ther; 2006 Sep; 24 Suppl 1():10-6. PubMed ID: 16939424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis.
    Hanauer SB
    Aliment Pharmacol Ther; 2006 Oct; 24 Suppl 3():37-40. PubMed ID: 16961743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. "Take your medicine": nonadherence issues in patients with ulcerative colitis.
    Turnbough L; Wilson L
    Gastroenterol Nurs; 2007; 30(3):212-7; quiz 218-9. PubMed ID: 17568260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral 5-ASA therapy in ulcerative colitis: what are the implications of the new formulations?
    Sandborn WJ
    J Clin Gastroenterol; 2008 Apr; 42(4):338-44. PubMed ID: 18277908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Refractory distal ulcerative colitis responsive to 5-aminosalicylate enemas.
    Barber GB; Lee DE; Antonioli DA; Peppercorn MA
    Am J Gastroenterol; 1985 Aug; 80(8):612-4. PubMed ID: 2862789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-molecular-weight heparin (enoxaparin) as adjuvant therapy in the treatment of active ulcerative colitis: a randomized, controlled, comparative study.
    Zezos P; Papaioannou G; Nikolaidis N; Patsiaoura K; Papageorgiou A; Vassiliadis T; Giouleme O; Evgenidis N
    Aliment Pharmacol Ther; 2006 May; 23(10):1443-53. PubMed ID: 16669959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review article: maintenance therapy in patients with ulcerative colitis.
    Orchard T; Probert CS; Keshav S
    Aliment Pharmacol Ther; 2006 Sep; 24 Suppl 1():17-22. PubMed ID: 16939425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review article: evolving concepts in treatment and disease modification in ulcerative colitis.
    Hanauer SB
    Aliment Pharmacol Ther; 2008 Mar; 27 Suppl 1():15-21. PubMed ID: 18307645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review article: 5-aminosalicylate formulations for the treatment of ulcerative colitis--methods of comparing release rates and delivery of 5-aminosalicylate to the colonic mucosa.
    Lichtenstein GR; Kamm MA
    Aliment Pharmacol Ther; 2008 Sep; 28(6):663-73. PubMed ID: 18532992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.